Bacteria use a virus's own enzyme as an immune alarm

Overview

Updated 53 minutes ago

Bacteria have a last-resort defense against viruses: the infected cell kills itself before the virus can spread. New research shows the virus's own enzyme is the alarm that triggers this suicide switch.

The discovery, published in Science, explains how the CBASS immune pathway detects phage infection. It could help researchers design better phage therapies for antibiotic-resistant infections, and it reveals an immune mechanism bacteria share with humans.

Why it matters

Understanding how bacteria detect phages could make phage therapy a reliable weapon against antibiotic-resistant infections.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

CD-NTase clades with identified activation loops

Clades A, D, and G of the CD-NTase enzyme family carry the protease-cleavable activation loop.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Sam Hobbs

Lead researcher, University of Utah Health

Lead author of the Science paper on CBASS activation

Philip J. Kranzusch

Co-author of the Science paper

Co-discoverer of the CBASS activation mechanism

Organizations Involved

University of Utah Health

Academic medical center

Research institution where the discovery was made

University of Utah Health is the academic medical center where Sam Hobbs conducted the research.

Science Corporation

Peer-reviewed scientific journal

Published the research

Science published the paper on October 1, 2026.

Timeline

2 events Latest: 3 days ago

October 2026
University of Utah Health announces the discovery
Latest Announcement

The university publicizes the finding that a viral enzyme cutting a bacterial sensor protein triggers a self-destructing immune response.
3 days ago
Science publishes CBASS activation paper
Publication

Hobbs and Kranzusch publish findings showing phage prohead proteases activate CBASS immunity by cleaving CD-NTase enzymes.
October 1st, 2026

Scenarios

Phage therapy engineered to bypass CBASS enters clinical trials

Possible Resolves by End of 2028

Discussed by: University of Utah Health researchers and phage therapy developers

The discovery identifies the exact protease cleavage site on CD-NTase enzymes. Researchers could engineer therapeutic phages that avoid triggering CBASS, making phage therapy more reliable against antibiotic-resistant bacteria. This would require modifying phage prohead proteases or the phage genome to evade detection.

Researchers map CBASS activation across more phage families

Likely Resolves by End of 2027

Discussed by: Hobbs and colleagues; the Science paper notes cleavable enzymes in a range of bacteria

The current study identified activation loops in clade A, D, and G CD-NTases and showed recognition of phage T4. Follow-up work could map how other phage families trigger CBASS, revealing the full range of viral threats bacteria can detect through protease activity.

Protease-triggered immune activation found in human cells

Unlikely Resolves by End of 2028

Discussed by: Hobbs, who noted CBASS is related to human immune pathways

CBASS is evolutionarily related to cGAS-STING in humans. The finding that proteases can trigger immune signaling in bacteria raises the question of whether similar protease-based detection exists in human innate immunity. This would require demonstrating that a human protease cleaves a cGAS-STING pathway component to activate signaling.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2012

CRISPR-Cas9 discovery (2012)

Researchers discovered that CRISPR-Cas9, a bacterial adaptive immune system that cuts viral DNA, could be programmed to edit any DNA sequence. Jennifer Doudna, Emmanuelle Charpentier, and colleagues published the foundational work.

Then

Within years, CRISPR became the standard tool for gene editing in labs worldwide.

Now

Doudna and Charpentier won the 2020 Nobel Prize in Chemistry. CRISPR-based therapies are now in clinical trials.

Why this matters now

Like CRISPR, CBASS is a bacterial immune system whose study could yield powerful biotechnology tools. Understanding how bacteria detect phages could improve phage therapy.

2012-2013

cGAS-STING pathway discovery (2012-2013)

Scientists identified cGAS as the cytosolic DNA sensor that activates STING, triggering innate immune responses. This pathway is the human counterpart to CBASS.

Then

The discovery explained how cells detect DNA in the cytoplasm and launched a wave of research into innate immunity.

Now

cGAS-STING is now a major drug target for cancer immunotherapy and autoimmune disease.

Why this matters now

CBASS is evolutionarily related to cGAS-STING. The new finding that proteases activate CBASS raises questions about whether similar mechanisms exist in human immunity.